Form 8-K - Current report:
SEC Accession No. 0001178913-25-000130
Filing Date
2025-01-15
Accepted
2025-01-15 16:01:41
Documents
17
Period of Report
2025-01-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zk2532553.htm   iXBRL 8-K 55513
2 EXHIBIT 10.1 exhibit_10-1.htm EX-10.1 39011
3 EXHIBIT 99.1 exhibit_99-1.htm EX-99.1 11856
8 image00003.jpg GRAPHIC 23647
  Complete submission text file 0001178913-25-000130.txt   335457

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA slxn-20250115.xsd EX-101.SCH 4741
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE slxn-20250115_def.xml EX-101.DEF 18264
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE slxn-20250115_lab.xml EX-101.LAB 27749
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE slxn-20250115_pre.xml EX-101.PRE 20506
20 EXTRACTED XBRL INSTANCE DOCUMENT zk2532553_htm.xml XML 6552
Mailing Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606
Business Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606 972-8-6286005
Silexion Therapeutics Corp (Filer) CIK: 0002022416 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42253 | Film No.: 25532905
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)